Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Open Orphan Plc ( (GB:HVO) ) has provided an announcement.
hVIVO plc, a specialist CRO focused on human challenge trials and early-stage drug development, serves a broad biopharma client base including most of the world’s largest drug makers. Its integrated platform spans preclinical work through Phase II and III studies, supported by dedicated clinical sites, laboratory services, and patient recruitment via FluCamp.
The company said it will publish its final results for the year to 31 December 2025 on 15 April 2026, alongside briefings for equity analysts and an online presentation for investors hosted by CEO Yamin ‘Mo’ Khan and CFO Stephen Pinkerton. The planned results day engagement underlines hVIVO’s ongoing investor outreach as it seeks to showcase performance across its human challenge, laboratory, and early-phase trial operations.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £7.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on HVO Stock
According to Spark, TipRanks’ AI Analyst, HVO is a Outperform.
Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.
To see Spark’s full report on HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase contract research organisation specialising in human challenge clinical trials across infectious and respiratory diseases. The company operates the world’s largest quarantine facility in London, provides virology and immunology lab services under the hLAB brand, and runs early-phase clinical trial units in Germany through its CRS subsidiary and consulting and biometry services via Venn Life Sciences.
Average Trading Volume: 3,352,699
Technical Sentiment Signal: Sell
Current Market Cap: £44.06M
Find detailed analytics on HVO stock on TipRanks’ Stock Analysis page.